197 assets in Follicular Lymphoma

Therapeutic assets addressing Follicular Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ace1831 Follicular Lymphoma	Acepodia Biotech, Inc.	P1	CC (40)
ct1182 Follicular Lymphoma	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Early P1	C (38)
Abbv-319 Follicular Lymphoma	AbbVie	P1	C (37)
BP1002 Follicular Lymphoma	Bio-Path Holdings, Inc.	P1	C (37)
Car.K.28 Follicular Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	C (37)
cd19.20.22 car t cells Follicular Lymphoma	University of Maryland, Baltimore	P1	C (37)
cd22 car-t Follicular Lymphoma	Stanford University	P1	C (37)
cd79b-19 car t cells Follicular Lymphoma	Marcela V. Maus, M.D.,Ph.D.	P1	C (37)
Docirbrutinib Follicular Lymphoma	Carna Biosciences, Inc.	P1	C (37)
Hmpl-760 Follicular Lymphoma	Hutchmed	P1	C (37)
iks03 Follicular Lymphoma	Iksuda Therapeutics Ltd.	P1	C (37)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Follicular Lymphoma	OncoNano Medicine, Inc.	P1	C (37)
Jwcar239 Follicular Lymphoma	Peking University Cancer Hospital & Institute	P1	C (37)
lp-168 Follicular Lymphoma	Newave Pharmaceutical Inc	P1	C (37)
lv20.19 car t cells Follicular Lymphoma	Medical College of Wisconsin	P1	C (37)
ly4584180 Follicular Lymphoma	Eli Lilly and Company	P1	C (37)
Neovax Follicular Lymphoma	Dana-Farber Cancer Institute	P1	C (37)
Onm-501 Follicular Lymphoma	OncoNano Medicine, Inc.	P1	C (37)
PRT1419 Follicular Lymphoma	Prelude Therapeutics	P1	C (37)
psb202 Follicular Lymphoma	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)	P1	C (37)
Sgr-1505 Follicular Lymphoma	Schrödinger, Inc.	P1	C (37)
Stk-009 Follicular Lymphoma	Synthekine	P1	C (37)
Syncar-001 Follicular Lymphoma	Synthekine	P1	C (37)
Synkir-310 Follicular Lymphoma	Verismo Therapeutics	P1	C (37)
Allogeneic Natural Killer Cells Follicular Lymphoma	Paolo Caimi, MD	P1	C (35)
Ari-0001 Follicular Lymphoma	GUSTAVO SALGUERO	N/A	C (35)
ft596 Follicular Lymphoma	Fate Therapeutics	P1	C (35)
64Cu-LLP2A Follicular Lymphoma	Washington University School of Medicine	Early P1	C (34)
rd14-01 cell Follicular Lymphoma	He Huang	Early P1	C (34)
Bexarotene Follicular Lymphoma	Case Comprehensive Cancer Center	N/A	D (30)
Kenacort Follicular Lymphoma	Case Comprehensive Cancer Center	N/A	D (30)
Magrolimab Follicular Lymphoma	National Cancer Institute (NCI)	P1	D (30)
ms-553 Follicular Lymphoma	MingSight Pharmaceuticals, Inc	P1/2	D (30)
Mtm-H-001 Follicular Lymphoma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	N/A	D (30)
Nitrogen Mustard Follicular Lymphoma	Case Comprehensive Cancer Center	N/A	D (30)
Apg-3288 Follicular Lymphoma	Ascentage Pharma Group Inc.	P1	NR ()
CD47/SIRPA-BLOCKING AGENT ALX148 Follicular Lymphoma	M.D. Anderson Cancer Center	P1/2	NR ()
Oncoquest-L Vaccine Follicular Lymphoma	XEME Biopharma Inc.	P2	NR ()
xnw5004 Follicular Lymphoma	Evopoint Biosciences Inc.	P2	NR ()

Showing 151 to 197 of 197 assets

PreviousPage 4 of 4Next